US 12,419,958 B2
Clinical formulations
Roger Gay, Acton, MA (US); Judson Ratliff, Harvard, MA (US); and Romma E. Southwick, Waban, MA (US)
Assigned to Astellas Institute for Regenerative Medicine, Westborough, MA (US)
Filed by Astellas Institute for Regenerative Medicine, Westborough, MA (US)
Filed on Mar. 15, 2024, as Appl. No. 18/606,927.
Application 18/606,927 is a division of application No. 17/210,448, filed on Mar. 23, 2021, granted, now 11,957,754.
Application 17/210,448 is a division of application No. 15/753,232, granted, now 11,013,808, previously published as PCT/US2016/047545, filed on Aug. 18, 2016.
Claims priority of provisional application 62/206,821, filed on Aug. 18, 2015.
Prior Publication US 2024/0350639 A1, Oct. 24, 2024
Int. Cl. A61K 47/26 (2006.01); A61K 9/08 (2006.01); A61K 31/7004 (2006.01); A61K 31/728 (2006.01); A61K 33/06 (2006.01); A61K 33/14 (2006.01); A61K 35/28 (2015.01); A61K 35/30 (2015.01); A61K 47/02 (2006.01); A61K 47/12 (2006.01); A61K 47/36 (2006.01); A61P 27/02 (2006.01)
CPC A61K 47/26 (2013.01) [A61K 9/08 (2013.01); A61K 31/7004 (2013.01); A61K 31/728 (2013.01); A61K 33/06 (2013.01); A61K 33/14 (2013.01); A61K 35/28 (2013.01); A61K 35/30 (2013.01); A61K 47/02 (2013.01); A61K 47/12 (2013.01); A61K 47/36 (2013.01); A61P 27/02 (2018.01)] 18 Claims
 
1. A solution for cell reconstitution, storage, transport and/or administration to a subject comprising
(a) a buffer, maintaining the solution at a physiological pH, optionally wherein the buffer is an acetate buffer and/or a citrate buffer;
(b) 13-19 mM glucose;
(c) 1-2.5 mM KCl;
(d) an osmotically active agent maintaining the solution at a physiological osmolarity; and
(e) a source of divalent cations, comprising a calcium source and a magnesium source,
wherein the solution does not comprise a carbonate buffer or a zwitterionic organic buffer, and further does not comprise glutathione or glutathione disulfide.